On Nov 07, major Wall Street analysts update their ratings for $Rhythm Pharmaceuticals (RYTM.US)$, with price targets ranging from $59 to $80.
Morgan Stanley analyst Jeffrey Hung maintains with a buy rating, and adjusts the target price from $55 to $72.
Goldman Sachs analyst Corinne Johnson maintains with a buy rating, and adjusts the target price from $57 to $59.
Wells Fargo analyst Derek Archila maintains with a buy rating, and adjusts the target price from $53 to $80.
TD Cowen analyst Phil Nadeau maintains with a buy rating, and maintains the target price at $65.
Needham analyst Joseph Stringer maintains with a buy rating, and adjusts the target price from $55 to $64.
Furthermore, according to the comprehensive report, the opinions of $Rhythm Pharmaceuticals (RYTM.US)$'s main analysts recently are as follows:
The firm is enhancing its projected probability of success for IMCIVREE's Phase 3 trial in HO following obesity week, and has incorporated risk-adjusted value for RM-718/LB54640 within the company's MC4R franchise. The expectation is for the company's shares to experience an upward trend in anticipation of multiple catalysts projected for 2025.
Rhythm Pharmaceuticals' BBS launch is experiencing robust and consistent growth, as evidenced by 100 new US prescriptions and 80 approvals for reimbursement in the third quarter. The company's pipeline is advancing towards significant milestones.
Here are the latest investment ratings and price targets for $Rhythm Pharmaceuticals (RYTM.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月7日，多家華爾街大行更新了$Rhythm Pharmaceuticals (RYTM.US)$的評級，目標價介於59美元至80美元。
摩根士丹利分析師Jeffrey Hung維持買入評級，並將目標價從55美元上調至72美元。
高盛集團分析師Corinne Johnson維持買入評級，並將目標價從57美元上調至59美元。
富國集團分析師Derek Archila維持買入評級，並將目標價從53美元上調至80美元。
TD Cowen分析師Phil Nadeau維持買入評級，維持目標價65美元。
Needham分析師Joseph Stringer維持買入評級，並將目標價從55美元上調至64美元。
此外，綜合報道，$Rhythm Pharmaceuticals (RYTM.US)$近期主要分析師觀點如下：
以下爲今日6位分析師對$Rhythm Pharmaceuticals (RYTM.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
